A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.
Also called NCT04865770
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 106 participants
- Sponsor
- Registry
-
NCT04865770 -
2020-000828-19
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Denmark, France, Italy, Poland, South Africa, Spain
- Registry status
- Completed
Technical summary
Registry record NCT04865770. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-28 (actual); primary completion 2024-11-21 (actual). Results posted on 2026-01-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
- Acronym
- REMODEL
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo (Semaglutide)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04865770- Content hash
201b2b73e04f179101e3414f08ae1ad34a7954da3ecd10a25f4818b7c8da84a6